Auclin, E., Mezquita, L., & Besse, B. (2021). Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176. Cancers (Basel).
Citação norma ChicagoAuclin, Edouard, Laura Mezquita, and Benjamin Besse. "Comment On Hopkins Et Al. Value of the Lung Immune Prognostic Index in Patients With Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176." Cancers (Basel) 2021.
Citação norma MLAAuclin, Edouard, Laura Mezquita, and Benjamin Besse. "Comment On Hopkins Et Al. Value of the Lung Immune Prognostic Index in Patients With Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176." Cancers (Basel) 2021.